Pharma Mar SA stock analysis
Pharma Mar SA (0RC6) Share Price & Analysis
0RC6 Stock Chart & Stats
- Day’s Range
- EUR 64.25 - EUR 66.20
- 52-Week Range
- EUR 62.40 - EUR 105.40
- Previous Close
- EUR 66.65
- Volume
- N/A
- Average Volume (3M)
- 1,107
- Market Cap
- EUR 1.14B
- Enterprise Value
- EUR 1.16B
- Total Cash (Recent Filing)
- EUR 176.29M
- Total Debt (Recent Filing)
- EUR 70.07M
- Price to Earnings (P/E)
- 16.2
- Beta
- 0.45
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- 0.4
- Last Dividend Ex-Date
- Jul 08, 2026
- Dividend Yield
- 1.54%
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Positive revenue growth indicates stronger commercial traction and expanding demand for the company’s oncology portfolio. If sustained, this growth can support operating leverage, increase resources available for research and development, and strengthen Pharma Mar’s position with commercial partners over the next several quarters.
Recent Profitability
Strong current profitability provides an important foundation for a research-driven biopharmaceutical business, helping fund pipeline development and commercial activities internally. Healthy margins also offer greater resilience if product sales or collaboration income fluctuate during the next two to six months.
Manageable Leverage
Moderate debt relative to equity reduces pressure on operating cash flow and preserves flexibility for investment in oncology development and commercialization. This balance-sheet position gives Pharma Mar more capacity to manage business volatility than a highly leveraged capital structure would allow.
Bears Say
Cash-Flow Volatility
Uneven cash generation makes the company’s financial progress less dependable than its recent earnings suggest. Declining free cash flow and prior periods of negative operating cash flow can constrain internally funded research, commercialization, and partnering initiatives if volatility persists.
Balance-Sheet Cushion
The recent combination of higher debt and slightly lower equity reduces the balance-sheet cushion available if earnings weaken. Although leverage remains manageable, this trend could limit financial flexibility and increase reliance on future operating performance to support investment and obligations.
Earnings Volatility
Profitability has not been consistently durable across the reported periods, with near-break-even earnings and negative operating profitability in 2023. Such volatility indicates that strong TTM results may not fully represent normalized performance, complicating planning and long-term resource allocation.
0RC6 FAQ
What was Pharma Mar SA’s price range in the past 12 months?
What is Pharma Mar SA’s market cap?
When is Pharma Mar SA’s upcoming earnings report date?
How were Pharma Mar SA’s earnings last quarter?
Is Pharma Mar SA overvalued?
Does Pharma Mar SA pay dividends?
What is Pharma Mar SA’s EPS estimate?
How many shares outstanding does Pharma Mar SA have?
What happened to Pharma Mar SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pharma Mar SA?
What is the TipRanks Smart Score and how is it calculated?
Pharma Mar SA Stock Smart Score
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jose Maria Fernandez Sousa-Faro
- Employees
- 505
- Website
- www.pharmamar.com
- Address
- Avenida de los Reyes, 1, Madrid, 28770, ES
Pharma Mar SA (0RC6) Earnings & Revenues
0RC6 Earnings Call
Earnings Call SentimentPositive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.
View all GB:0RC6 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |










